Table 2. Correlation between ESR1 gene dosage and clinico-pathological data in the entire group and in the tamoxifen-treated patients.

Variable	All patients			Tamoxifen-treated patients
	N	Median ESR1 gene dosage (25-75 percentile)	P	N	Median ESR1 gene dosage (25-75 percentile)	P
T stage
T1-2	219	1.11 (0.85-1.39)	0.01	67	1.10 (0.86-1.24)	0.85
T3-4	59	1.25 (0.88-1.97)		7	1.13 (0.63-1.18)
N stage
0	148	1.08 (0.82-1.31)	0.008	54	1.11 (0.85-1.24)	0.78
1	129	1.17 (0.91-1.65)		19	1.07 (0.85-1.17)
Grade
1-2	121	1.11 90.89-1.41)	0.87	29	1.08 (0.85-1.17)	0.54
3	85	1.16 (0.87-1.47)		15	1.10 (0.92-1.21)
Histological type
Ductal	191	1.13 (0.87-1.56)	0.12	42	1.10 (0.91-1.23)	0.45
Lobular	51	1.01 (0.82-1.31)		19	0.95 (0.74-1.24)
ER status
Negative	120	1.20 (0.86-1.64)	0.12	22	1.10 (0.90-1.49)	0.26
Positive	161	1.10 (0.85-1.37)		53	1.08 (0.84-1.20)
PR status
Negative	131	1.11 (0.83-1.65)	0.75	22	1.10 (0.84-1.25)	1
Positive	150	1.11 (0.88-1.39)		53	1.10 (0.85-1.23)
HER2 status
Negative	182	1.10 (0.83-1.37)	0.75	47	1.08 (0.83-1.21)	0.50
Positive	29	1.11 (0.90-1.31)		9	1.20 (0.88-1.23)
Age
<50 yr.	68	1.18 (0.88-1.51)	0.53	19	1.20 (0.99-1.55)	0.05
≥50 yr.	213	1.10 (0.85-1.47)		56	1.06 (0.80-1.17)
Molecular subtype
Luminal A	60	1.10 (0.85-1.39)	1	13	1.08 (0.85-1.11)	0.71
Luminal B (HER2-)	38	1.13 (0.40-2.07)		11	1.05 (0.83-1.21)
Luminal B (HER2+)	15	1.17 (0.92-1.27)		8	1.21 (0.90-1.27)
HER2+	14	1.02 (0.87-1.71)		1	0.87
Triple negative	56	1.07 (0.80-1.43)		5	1.13 (0.63-1.16)
Allred score
0-2	20	1.03 (0.88-1.29)	0.56		-
3-6	27	1.12 (0.87-1.41)
7-8	41	1.18 (0.90-1.58)
ESR1 PvuII
wt/wt		Not analyzed		22	1.19 (1.10-1.31)	0.0003
wt/vt				30	1.07 (0.85-1.17)
vt/vt				16	0.77 (0.64-1.03)
CYP2C19
wt/wt		Not analyzed		56	1.10 (0.84-1.24)	0.58
wt/*2				10	1.11 (0.97-1.18)
*2/*2				2	0.89 (0.72-1.05)
UGT2B15
wt/wt		Not analyzed		19	1.04 (0.73-1.18)	0.54
wt/*2				33	1.10 (0.90-1.20)
*2/*2				15	1.11 (0.88-1.31)